DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Inhibition of ALK3-mediated signalling pathway protects against acetaminophen-induced liver injury
Acetaminophen (APAP)-induced liver injury is one of the most prevalent causes of acute liver failure (ALF). We assessed the role of the bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3 in APAP-induced hepatotoxicity. The molecular mechanisms that regulate the balance between cell death and survival and the response to oxidative stress induced by APAP was assessed in cultured human hepatocyte-derived (Huh7) cells treated with pharmacological inhibitors of ALK receptors and with modulated expression of ALK2 or ALK3 by lentiviral infection, and in a mouse model of APAP-induced hepatotoxicity. Inhibition of ALK3 signalling with the pharmacological inhibitor DMH2, or by silencing of ALK3, showed a decreased cell death both by necrosis and apoptosis after APAP treatment. Also, upon APAP challenge, ROS generation was ameliorated and, thus, ROS-mediated JNK and P38 MAPK phosphorylation was reduced in ALK3-inhibited cells compared to control cells. These results were also observed in an experimental model of APAP-induced ALF in which post-treatment with DMH2 after APAP administration significantly reduced liver tissue damage, apoptosis and oxidative stress. This study shows the protective effect of ALK3 receptor inhibition against APAP-induced hepatotoxicity. Furthermore, findings obtained from the animal model suggest that BMP signalling might be a new pharmacological target for the treatment of ALF., This study was supported by grants RTI2018-094203-B-I00 (to AMR), PID2020-11794RB-IOO (to FJC), PID2021-124688OB-I00 (to AMR) and PID2021-122766OB-100 (to AMV) and funded by MCIN/AEI/10.13039/501100011033 (Spain) and “ERDF A way of making Europe” by the European Union; the European Horizon's research and innovation programme HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679, funded by the European Union, and COST Action CA17112, supported by COST (European Cooperation in Science and Technology), to FJC, and contract CP19/00032, and grants PI16/00853 and PI19/00123 from Instituto de Salud Carlos III (ISCIII, Spain), partially funded by FEDER, and CIBERDEM (ISCIII, Spain) to AGR. FJC belongs to the validated Research Groups Ref. 970935 "Liver Pathophysiologÿ, 920631 "Lymphocyte immunobiologÿ, 920361 “Inmunogenética e inmunología de las mucosas” and IBL-6 (imas12-associated). CCF is supported by grant FPU18/03475 from the Ministerio de Universidades (Spain), partially funded by FEDER. PMB is supported by a research contracts (PEJD-2018-PRE/BMD-9500PEJ-2020-AI/BMD-19491) funded by Comunidad de Madrid (Spain). SCI is supported by a predoctoral contract (FI20-00296) from ISCIII/FEDER (Spain)., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 RTI2018-094203-B-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-117941RB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-124688OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-122766OB-I00
,
EC / HE 101095679